Video information: Inhibitors and targeted therapies have changed the landscape of CLL treatment, so what can patients expect from modern medicine? Dr. Jeff Sharman, from the US Oncology Network, joins our panel to explain the difference in design between newer therapies and chemotherapy. He also shares what newer medicines, like ibrutinib...
Read More
Video information: Tune in to hear how myeloma patient advocate, Alan Stephenson, finds inner strength to rise above his myeloma condition and maintain physical activity and peace of mind. Transcript: Jeff Folloder: One of the keys in recovery is to do what you don’t feel like doing. What exactly motivates you to do those things that you...
Read More
Video information: CLL patients can be prescribed steroids as a part of a treatment regimen, but how do they influence the body’s ability to reach remission? Expert, Dr. Michael Keating, joins us from The University of Texas MD Anderson Cancer Center, to describe the potential impact of steroids on treatment response. Transcript: Andrew...
Read More
Video Information Dr. Faith Davies, from the UAMS Myeloma Institute, and Dr. Brian Walker, from the University of Arkansas for Medical Sciences, share how tests showing abnormalities in gene expression can help classify myeloma patients, and how this information can help improve care for myeloma patients. Transcript Dr. Davies: I think there...
Read More
Video information: After receiving a successful treatment, it’s recommended that patients turn to maintenance therapy to help safeguard their quality of life and help control the residual myeloma cells from developing. The landscape for maintenance therapy continues to expand as the potential effects of new immuno-drugs emerge. Listen in as...
Read More
Video information: In this informative and optimistic edition of “Ask the Expert,” Dr. Gareth Morgan, Professor of Medicine and Director of the UAMS Myeloma Institute, reveals what health prerequisites multiple myeloma patients must reach before they can become cured and what tools are available to help attain that goal. He also poses...
Read More
Video information: Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant....
Read MoreVideo Information: The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell...
Read More
Video information: On location at the recent 2017 American Society of Clinical Oncology meeting (ASCO), Dr. Hearn Jay Cho of Mount Sinai Hospital discusses news out of ASCO 2017 and what it means for myeloma patients and care partners. Dr. Cho highlights news out of the meeting, including how experts are manipulating the immune system, precision...
Read More
Video information: Are there new developments in treating metastatic lung cancer? Dr. David Carbone of Ohio State University Comprehensive Cancer Center has much to report. From new medications that directly impact quality of life, rapid research to patients who are outliving their original prognosis, Dr. Carbone weighs in on...
Read MoreVideo information: Treatments that inhibit CLL, such as BTK Inhibitors, are becoming more commonly used in patients. So, how do they work? CLL expert Dr. John Burke explains the mechanism of action that inhibitor therapies use to treat CLL. Dr. Burke also discusses how inhibitors affect cancer proteins and how they differ from...
Read More
In a nutshell This study looked survival rates of stage II rectal cancer patients who underwent different treatments. It compared radical surgery versus local excision with added-on chemoradiation. The article concluded that overall survival was not different between the treatments. Some background Radical surgery (RS – complete...
Read More
